Eupraxia Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Eupraxia Pharmaceuticals has a total shareholder equity of $13.3M and total debt of $4.6M, which brings its debt-to-equity ratio to 34.1%. Its total assets and total liabilities are $25.0M and $11.6M respectively.
Key information
34.1%
Debt to equity ratio
US$4.55m
Debt
| Interest coverage ratio | n/a |
| Cash | US$23.32m |
| Equity | US$13.34m |
| Total liabilities | US$11.64m |
| Total assets | US$24.98m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EPRX's short term assets ($24.5M) exceed its short term liabilities ($11.6M).
Long Term Liabilities: EPRX's short term assets ($24.5M) exceed its long term liabilities ($35.0K).
Debt to Equity History and Analysis
Debt Level: EPRX has more cash than its total debt.
Reducing Debt: EPRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EPRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EPRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36.5% each year